2 Minute QuickTips from the APSHO Experts

APs: Need some clinical advice? Got 2 minutes? Watch our clinical oncology experts talk about the latest topics that will get you up to speed on current advances in the field. Here you’ll find a range of topics where you can increase your knowledge quickly and then, when you have more than 2 minutes, you can participate in a deeper dive on each topic by accessing the full accredited version at JADPRO CE. Come back often as we are continually updating our 2 minute tips!


Search by:

How do I distinguish between prescribed drugs, parent biologics, and competing biosimilars?

Kelley Mayden, MSN, FNP, AOCNP

Watch Video

 

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

How does a biosimilar compare to its reference product?

Kelley Mayden, MSN, FNP, AOCNP

Watch Video

 

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

What are the biosimilars with current or pending approval from the FDA?

Christopher J. Campen, PharmD, BCOP

Watch Video

 

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

Is it important for me to be involved in post-market studies of biosimilars?

Christopher J. Campen, PharmD, BCOP

Watch Video

 

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

How do you educate patients about the timing of early and latent side effects?

Mollie Reed, MSN, RN, ACNP-BC

Watch Video


Main Session: Overview of Immunotherapy

What cancers are most likely to respond to immunotherapy?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Watch Video


Main Session: Overview of Immunotherapy

How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Watch Video


Main Session: Overview of Immunotherapy

What are the mechanisms of action and adverse effects of these agents?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA

Watch Video


Main Session: Overview of Immunotherapy

Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?

Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Watch Video


Main Session: Overview of Immunotherapy

When should you image patients to assess response to immunotherapy?

Mollie Reed, MSN, RN, ACNP-BC

Watch Video


Main Session: Overview of Immunotherapy

Is programmed cell death ligand 1 (PD-L1) testing necessary?

Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Watch Video


Main Session: Overview of Immunotherapy

What are the mechanisms of action of targeted treatments and immunotherapies?

Whitney Lewis

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

What is the current thinking on diagnosis and treatment of patients with squamous cell NSCLC?

Frank E. Mott

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

What are the genetic variants in NSCLC, and how are they used to select treatment?

Frank E. Mott

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

How do you interpret a patient’s therapeutic response to treatment?

Melinda Oliver

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

How do you identify and manage adverse events?

Melinda Oliver

Watch Video


Main Session: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

What are some of the emerging therapies and their mechanisms of action?

Beth Faiman
PhD, MSN, APRN-BC, AOCN
Cleveland Clinic

Watch Video


Main Session: Updates in Multiple Myeloma

What are some of the emerging therapies and how do you select and sequence treatments?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Hodgkin Lymphoma

How do you select and sequence treatments in the upfront and relapsed/refractory settings?

Beth Faiman
PhD, MSN, APRN-BC, AOCN
Cleveland Clinic

Watch Video


Main Session: Updates in Multiple Myeloma

What should you be aware of when monitoring for toxicities linked with newer agents?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Hodgkin Lymphoma

What should you be aware of when monitoring for toxicities linked with newer agents?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What are the best ways to help patients adhere to oral therapies?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What is the role of the advanced practitioner in the cancer care team?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What should you be aware of when monitoring for toxicities linked with newer agents?

Beth Faiman
PhD, MSN, APRN-BC, AOCN
Cleveland Clinic

Watch Video


Main Session: Updates in Multiple Myeloma

What are some of the emerging therapies and how do you select and sequence treatments?

Sandra E. Kurtin
PhDc, ANP-C, AOCN
Arizona Cancer Center

Watch Video


Main Session: Updates in Non-Hodgkin Lymphoma

What are some of the emerging therapies and their mechanisms of action?

Ann McNeill
RN, MSN, APN
John Theurer Cancer Center
Hackensack University Medical Center

Watch Video


Main Session: Updates in Chronic Lymphocytic Leukemia

What should you be aware of when monitoring for toxicities linked with newer agents?

Ann McNeill
RN, MSN, APN
John Theurer Cancer Center
Hackensack University Medical Center

Watch Video


Main Session: Updates in Chronic Lymphocytic Leukemia

How do you optimize patient outcomes when adverse events occur?

Ann McNeill
RN, MSN, APN
John Theurer Cancer Center
Hackensack University Medical Center

Watch Video


Main Session: Updates in Chronic Lymphocytic Leukemia

Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here